Fecal Microbiota Transplantation & Chronic liver disease
Fecal Microbiota Transplantation for Chronic Liver Diseases: Current Understanding and Future Direction.
Acute-on-chronic liver failure in patients with alcohol-related liver disease.
Are There Potential Applications of Fecal Microbiota Transplantation beyond Intestinal Disorders?
Fecal Microbiota Transplantation for Clostridioides Difficile Infection in Patients with Chronic Liver Disease.
Gut-Liver Axis, Gut Microbiota, and Its Modulation in the Management of Liver Diseases: A Review of the Literature.
Gut microbiota and hepatitis-B-virus-induced chronic liver disease: implications for faecal microbiota transplantation therapy.
Review article: the gut microbiome as a therapeutic target in the pathogenesis and treatment of chronic liver disease.
Organ transplantation and gut microbiota: current reviews and future challenges.
Alterations in Intestinal Microbiota Lead to Production of Interleukin 17 by Intrahepatic gammadelta T-Cell Receptor-Positive Cells and Pathogenesis of Cholestatic Liver Disease.
Gut-liver axis, cirrhosis and portal hypertension: the chicken and the egg.
Molecular phenomics and metagenomics of hepatic steatosis in non-diabetic obese women.
Update on the Therapeutic Management of Hepatic Encephalopathy.
Severe alcoholic hepatitis: current perspectives.
microbiome in primary sclerosing cholangitis: A review.
Chronic Liver Diseases and the Microbiome: Translating Our Knowledge of Gut Microbiota to Management of Chronic Liver Disease.
Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT).
Metabolite identification in fecal microbiota transplantation mouse livers and combined proteomics with chronic unpredictive mild stress mouse livers.
A story of liver and gut microbes: how does the intestinal flora affect liver disease? A review of the literature.
Dietary approach and gut microbiota modulation for chronic hepatic encephalopathy in cirrhosis.
Mechanistic and therapeutic advances in non-alcoholic fatty liver disease by targeting the gut microbiota.
Human Gut Microbiome Transplantation in Ileitis Prone Mice: A Tool for the Functional Characterization of the Microbiota in Inflammatory Bowel Disease Patients.
The role of the gut microbiome in chronic liver disease: the clinical evidence revised.
The Candida albicans exotoxin candidalysin promotes alcohol-associated liver disease.
Targeting the Gut Microbiome as a Treatment for Primary Sclerosing Cholangitis: A Conceptional Framework.
Immunological mechanisms underpinning faecal microbiota transplantation for the treatment of inflammatory bowel disease.
Management of the Patient with Chronic Intestinal Pseudo-Obstruction and Intestinal Failure.
Review article: can bugs be drugs? The potential of probiotics and prebiotics as treatment for non-alcoholic fatty liver disease.
Purinergic signaling during intestinal inflammation.
The Relationship between Choline Bioavailability from Diet, Intestinal Microbiota Composition, and Its Modulation of Human Diseases.
The effect of fecal microbiota transplantation on Hepatic myelopathy: A case report.
Durability Of Response To Fecal Microbiota Transplantation After Exposure to Risk Factors for Recurrence In Patients With Clostridioides difficile Infection.
Microbiome alterations observed in liver diseases present opportunities for potential fecal transplantation.
Gut microbiota generation of protein-bound uremic toxins and related metabolites is not altered at different stages of chronic kidney disease.
Microbial Metabolites: Critical Regulators in NAFLD.
The Microbiome and Primary Sclerosing Cholangitis.
Emerging treatments for primary sclerosing cholangitis.
Acute-on-chronic liver failure vs. traditional acute decompensation of cirrhosis.
New Therapeutic Strategies for Primary Sclerosing Cholangitis.
Fecal microbiota transplantation induces hepatitis B virus e-antigen (HBeAg) clearance in patients with positive HBeAg after long-term antiviral therapy.
Microbiota transplantation reveals beneficial impact of berberine on hepatotoxicity by improving gut homeostasis.
Management of Hepatic Encephalopathy Not Responsive to First-Line Treatments.
Current trials and novel therapeutic targets for alcoholic hepatitis.
Microbiome Regulation of Autoimmune, Gut and Liver Associated Diseases.
Profile of Gut Microbiota Associated With the Presence of Hepatocellular Cancer in Patients With Liver Cirrhosis.
Therapeutic modulation of gut microbiota: current clinical applications and future perspectives.
Hydroxytyrosol Improves Obesity and Insulin Resistance by Modulating Gut Microbiota in High-Fat Diet-Induced Obese Mice.
Restoration of a healthy intestinal microbiota normalizes portal hypertension in a rat model of nonalcoholic steatohepatitis.
Analysis of the Relationship Between the Degree of Dysbiosis in Gut Microbiota and Prognosis at Different Stages of Primary Hepatocellular Carcinoma.
Parasutterella, in association with irritable bowel syndrome and intestinal chronic inflammation.
Faecal microbiota transplantation in patients with Clostridium difficile and significant comorbidities as well as in patients with new indications: A case series.
Acute ileitis facilitates infection with multidrug resistant Pseudomonas aeruginosa in human microbiota-associated mice.
Intestinal inflammation modulates expression of the iron-regulating hormone hepcidin depending on erythropoietic activity and the commensal microbiota.
Ethyl pyruvate decreases HMGB1 release and ameliorates murine colitis.